<DOC>
	<DOCNO>NCT03043677</DOCNO>
	<brief_summary>To characterize circulate DC subset healthy control IBD patient assess , follow ex vivo challenge , effect anti-TNF ( infliximab , adalimumab golimumab ) , anti-p40 -IL-12/IL-23- ( ustekinumab ) anti-α4β7 ( vedolizumab ) immunomodulators GI production soluble immune mediator mucosal capacity alter recruitment capacity circulate DC subset . It expect approach provide information action mechanism therapy IBD patient , allow well understanding pathophysiology disease identification tissue-specific therapeutic target , thus avoid collateral problem associate systemic immunomodulation .</brief_summary>
	<brief_title>Ex-vivo Modulatory Effect Biological Drugs Inflammatory Bowel Disease Mucosa Peripheral Blood Mononuclear Cells</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients active IBD , endoscopic histological diagnosis CD UC attend colonoscopy sedation perform medical criterion . Patients without IBD diagnosis , type inflammatory , allergic , malignant autoimmune disease , prior inclusion project . All patient attend colonoscopy sedation medical judgment biopsy indication histopathological study case diarrhea also due change bowel transit , rectal bleed screen gastrointestinal disease . Patients paired age gender IBD group . All patient sign macroscopic microscopic inflammation hence exclude presence microscopic colitis . 1 . Age le 18 year 2 . Chronic disease advance clinically significant pathology , uncontrolled investigator judgment . 3 . Should medication , unchanged 3 month prior colonoscopy . 4 . Alcohol drug . 5 . Pregnancy lactation 6 . Do sign inform consent form ( see `` Ethical Issues '' ) In case NO colonoscopy exclusively target sample project make</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>